Radiotherapy is one of the most common countermeasures for treating a wide range of
tumors. However, the radioresistance of cancer cells is still a major limitation for …

Among all existing radionuclides, only a few are of interest for therapeutic applications and
more specifically for targeted alpha therapy (TAT). From this selection, actinium-225 …

Summary Background Lutetium-177 (177 Lu) prostate-specific membrane antigen (177 Lu-
PSMA) is a novel targeted treatment for patients with metastatic castration-resistant prostate …

Purpose: Fibroblast activation protein (FAP) is a promising target for tumor treatment. In this
study, we aimed to investigate the safety and efficacy of the albumin binder-conjugated FAP …

The International Commission on Radiation Units and Measurements (ICRU), since its
inception in 1925, has had as its principal objective the development of internationally …

The use of prostate-specific membrane antigen (PSMA)-directed applications in modern
prostate cancer management has evolved rapidly over the past few years, helping to …

Prostate-specific membrane antigen (PSMA)-targeting radio-ligand therapy with beta-
emitting 177 Lutetium has already been investigated in several early phase dosimetry …

Objective Evidence shows that gene mutation is a significant proportion of genetic factors
associated with prostate cancer. The DNA damage response (DDR) is a signal cascade …

Simple Summary Currently, there is no treatment that can cure patients with late stage
metastatic prostate cancer. Prostate-specific membrane antigen is a type of protein …

225Ac-PSMA-617, targeting the prostate-specific membrane antigen (PSMA), which is
overexpressed on prostate cancer cells, has shown a remarkable therapeutic efficacy in …